Patient, tumor characteristics for high-mitotic rate melanoma

August 20, 2014

A study in Australia examined patient and tumor characteristics for melanomas with higher mitotic rates (a marker of tumor cell growth) in an effort to increase earlier detection of this aggressive cancer in patients.

The tumor characteristic known as mitotic rate (measure of cell division) has been connected with prognosis and survival in patients. However, the literature is scarce regarding the clinical presentation of high-mitotic rate melanoma, which could help in identifying those patients at risk for poor prognosis.

The authors included 1,441 patients with 1,500 primary invasive melanomas from a clinic in a public hospital in Australia in their study to determine patient and of high-mitotic rate melanoma. Of the 1,500 melanomas, 813 (54 percent) occurred in men and 687 presented in women.

Melanomas with higher mitotic rates were more likely to occur on the head and neck, be rapidly growing lesions (greater than or equal to 2 mm/per month), more often present as amelanotic (without pigmentation) and be found on older men (70 years or older) and those with a history of solar keratosis caused by sun damage. A history of blistering sunburns and family history of melanoma were associated with lower mitotic rate activity.

"The results from this single-center study merit replication elsewhere to confirm generalizability and to further explore the potential implications for detection and treatment of at-risk patients, who in this study were found to have a distinct phenotypic and historical profile. Mitotically active melanomas were more often seen in with chronic solar field damage. These tumors have a predilection for the head and neck and can present with nodular structure and amelanosis. Such atypical clinical features may pose a challenge to timely detection; thus a high index of suspicion is warranted when the patient reports a history of morphologic change and rapid growth." Sarah Shen, M.B.B.S., B.Med.Sci., of Alfred Hospital, in Victoria, Australia, and colleagues said in their JAMA Dermatology paper.

In a related editorial, Samuel J. Balin, M.D., Ph.D., of the University of California, Los Angeles, and Raymond L. Barnhill, M.D., M.Sc., of the University of California, Los Angeles Medical Center, write: "Clinician have no guidelines by which to estimate clinically which suspect lesions might have a high mitotic rate, and therefore pose more of a threat, and which might have a low mitotic rate and ultimately behave less aggressively. The study by Shen et al in this issue of JAMA Dermatology addresses this deficiency in knowledge and elucidates the clinical characteristics of rapidly growing tumors."

"Although this study was conducted in a scientifically sound fashion, certain aspects concerning the analysis and significance of mitotic rate in melanoma have not yet been resolved," the authors continued.

"Shen et al provide clinicians with more data and ultimately another tool to factor into their clinical decision-making process. By understanding the clinical characteristics of more rapidly growing tumors, clinicians can better guide their own screening and treatment decisions and better counsel patients, from diagnosis through treatment, and ultimately to prognosis," they conclude.

Explore further: New prognostic factors may be useful in staging melanoma

More information: JAMA Dermatology. Published online August 20, 2014. DOI: 10.1001/jamadermatol.2014.635
JAMA Dermatology. Published online August 20, 2014. DOI: 10.1001/jamadermatol.2014.924

Related Stories

New prognostic factors may be useful in staging melanoma

July 16, 2014
(HealthDay)—New prognostic factors may be useful in predicting survival in patients with thin melanoma, according to research published online July 7 in the Journal of Clinical Oncology.

Hypervigilance critical for difficult-to-detect melanoma

July 1, 2014
(HealthDay)—Monitoring patients at extreme risk with total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI) assists with early diagnosis of primary melanoma, according to a study published online ...

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

The number of tumor cells spread to sentinel lymph nodes affects melanoma prognosis

February 18, 2014
Cancer cell spread to the sentinel node—the lymph node to which cancer cells are most likely to spread from a primary tumor—is a risk factor for melanoma death. According to a study published in this week's PLOS Medicine ...

Dermatologist care tied to better self-detection of melanoma

April 25, 2014
(HealthDay)—Patients with self-detected primary melanoma who have an established dermatologist are more likely to have thinner lesions at the time of diagnosis, according to research published in the May issue of the Journal ...

Melanoma screening by physicians associated with finding more cancers than patient self-detection

July 18, 2011
Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma, according to a report published Online First today by Archives of Dermatology, one of ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.